Companies /Healthcare

Tempus AI, Inc. Class A Common Stock

NASDAQ: TEM Health Information Services
$71.44
â–² $2.96 (+4.32%) today
Markets open · 12:35pm ET

Q2 2026 Earnings

Reported Jul 30, 2026, 4:01pm ET · SEC source
$-0.04
Beat +73.63%
EPS · est. $-0.15
$382.5M
Beat +0.78%
Revenue · est. $379.5M
6 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−6%−3%0Jul 30Jul 31report 4:01pm ETearnings+0.1%−3.3%
−6%−3%0Jul 30Jul 31earnings+0.1%−3.3%
TEM −3.3%S&P 500 +0.1%
−6%−3%0Jul 30Jul 31report 4:01pm ETearnings−0.1%−3.3%
−6%−3%0Jul 30Jul 31earnings−0.1%−3.3%
TEM −3.3%NASDAQ −0.1%
0+8%+16%Jul 29Aug 7report 4:01pm ETearnings+4.2%+20.3%
0+8%+16%Jul 29Aug 7earnings+4.2%+20.3%
TEM +20.3%S&P 500 +4.2%
0+8%+16%Jul 29Aug 7report 4:01pm ETearnings+5.4%+20.3%
0+8%+16%Jul 29Aug 7earnings+5.4%+20.3%
TEM +20.3%NASDAQ +5.4%
−0.95%
Day of report
+4.97%
Next session
+18.65%
One week

Did TEM Beat Earnings? Q2 2026 Results

Tempus AI, Inc. delivered a strong second quarter for fiscal 2026, beating Wall Street expectations on both the top and bottom lines and extending its consensus EPS beat streak to five consecutive quarters. The AI-driven healthcare company posted a non-GAAP loss of just $0.04 per share against a consensus estimate of $0.15, a 73.63% positive surprise, while revenue of $382.49 million edged past estimates by 0.78% and grew 21.6% year over year. The standout driver was Diagnostics, where oncology testing volumes accelerated to 31% growth and gross margin widened to 62.6% from 58.8% a year ago, while the Data and Applications segment contributed $93.15 million, up 28%, anchored by roughly $200 million in newly signed data licenses with partners including BioNTech and Daiichi Sankyo. Analysts tracking the stock have maintained bullish stances heading into the print, and management rewarded that confidence by raising full-year 2026 revenue guidance to $1.59 to $1.60 billion, implying approximately 25% annual growth, while holding its Adjusted EBITDA target of roughly $65 million.

Key Takeaways
  • Oncology volume growth of 31% year-over-year, accelerating from 28% last quarter
  • Data Licensing & Modeling (Insights) revenue grew 36% year-over-year
  • Diagnostics gross margin expansion to 62.6% from 58.8% year-over-year
  • $98.5 million in unrealized gains on marketable securities contributed to GAAP net income

“Q2 was another exceptional quarter for us. Our strategy is working given the investments we have made in AI over the past several years are driving some of the best growth rates we have seen in our two largest businesses - Oncology Diagnostics and Data Licensing.”

Tempus AI CEO, on the earnings call

Forward Guidance & Outlook

Tempus increased its full-year 2026 revenue guidance to $1.595 to $1.605 billion, representing approximately 25% annual growth. The company continues to expect 2026 Adjusted EBITDA of approximately $65 million. Guidance assumes no impact from the pending Personalis acquisition, which is expected to close in late Q4 2026 or early 2027.

TEM YoY Financials

Q2 2026 vs Q2 2025 · SEC filings Q2 2025 Q2 2026
$0$200.0M$400.0M$314.6M$382.5MRevenue$195.0M$246.5MGross Profit$-98,447,672$-75,913,000Operating Income$2.6M$5.6MNet Income
$0$200.0M$400.0MRevenueGross ProfitOperating IncomeNet Income

TEM Revenue by Segment

Diagnostics$289.3M+20.0%
Genomics
Oncology Testing (Tempus genomics)
Oncology Testing (Tempus Genomics)
Oncology Testing
Hereditary Testing (Ambry Genetics)
Data and Applications$93.2M+28.0%
Data and Services

Figures from SEC filings and company reports. Not investment advice.